Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Antoine C. El Khoury, Carolyn Wallace, William K. Klimack & Homie Razavi. (2012) Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics 15:5, pages 887-896.
Read now
Read now
H Jafferbhoy, W Gashau & JF Dillon. (2010) Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. ClinicoEconomics and Outcomes Research 2, pages 87-96.
Read now
Read now
Jonathan Shepherd & Jeremy Jones. (2007) A systematic review of the cost–effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 577-595.
Read now
Read now
Articles from other publishers (19)
Qinglu Cheng, Veronica C. Hoad, Avijoy Roy Choudhury, Clive R. Seed, Peter Bentley, Sophy T. F. Shih, Jisoo A. Kwon, Richard T. Gray & Virginia Wiseman. (2023) Removing hepatitis C antibody testing for Australian blood donations: A cost‐effectiveness analysis. Vox Sanguinis 118:6, pages 471-479.
Crossref
Crossref
Jisoo A. Kwon, Gregory J. Dore, Behzad Hajarizadeh, Maryam Alavi, Heather Valerio, Jason Grebely, Rebecca Guy & Richard T. Gray. (2021) Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLOS ONE 16:9, pages e0257369.
Crossref
Crossref
Mawuena Binka, Naveed Z. Janjua, Jason Grebely, Chris Estes, Dena Schanzer, Jisoo A. Kwon, Naglaa H. Shoukry, Jeffrey C. Kwong, Homie Razavi, Jordan J. Feld & Mel Krajden. (2020) Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Network Open 3:5, pages e204192.
Crossref
Crossref
Chris Estes, Henry L. Y. Chan, Rong N. Chien, Wan‐Long Chuang, James Fung, George Boon-Bee Goh, Tsung H. Hu, Jee‐Fu Huang, Byoung K. Jang, Dae W. Jun, Jia H. Kao, Jin‐Woo Lee, Han‐Chieh Lin, Kathryn Razavi‐Shearer, Wai‐Kay Seto, Grace L. ‐H. Wong, Vincent W. ‐S. Wong & Homie Razavi. (2020) Modelling NAFLD disease burden in four Asian regions—2019‐2030. Alimentary Pharmacology & Therapeutics 51:8, pages 801-811.
Crossref
Crossref
Jisoo A. Kwon, Gregory J. Dore, Jason Grebely, Behzad Hajarizadeh, Rebecca Guy, Evan B. Cunningham, Cherie Power, Chris Estes, Homie Razavi & Richard T. Gray. (2018) Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of Viral Hepatitis 26:1, pages 83-92.
Crossref
Crossref
Behzad Hajarizadeh, Jason Grebely, Hamish McManus, Chris Estes, Homie Razavi, Richard T Gray, Maryam Alavi, Janaki Amin, Skye McGregor, William Sievert, Alexander Thompson & Gregory J Dore. (2017) Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment. Journal of Gastroenterology and Hepatology 32:1, pages 229-236.
Crossref
Crossref
A. Sibley, K. H. Han, A. Abourached, L. A. Lesmana, M. Makara, W. Jafri, R. Salupere, A. M. Assiri, A. Goldis, F. Abaalkhail, Z. Abbas, A. Abdou, F. Al Braiki, F. Al Hosani, K. Al Jaberi, M. Al Khatry, M. A. Al Mulla, H. Al Quraishi, A. Al Rifai, Y. Al Serkal, A. Alam, S. M. Alavian, H. I. Alashgar, S. Alawadhi, L. Al‐Dabal, P. Aldins, F. Z. Alfaleh, A. S. Alghamdi, R. Al‐Hakeem, A. A. Aljumah, A. Almessabi, A. N. Alqutub, K. A. Alswat, I. Altraif, M. Alzaabi, N. Andrea, M. A. Babatin, A. Baqir, M. T. Barakat, O. M. Bergmann, A. R. Bizri, S. Blach, A. Chaudhry, M. S. Choi, T. Diab, S. Djauzi, E. S. El Hassan, S. El Khoury, C. Estes, S. Fakhry, J. I. Farooqi, H. Fridjonsdottir, R. A. Gani, A. Ghafoor Khan, L. Gheorghe, M. Gottfredsson, S. Gregorcic, J. Gunter, B. Hajarizadeh, S. Hamid, I. Hasan, A. Hashim, G. Horvath, B. Hunyady, R. Husni, A. Jeruma, J. G. Jonasson, B. Karlsdottir, D. Y. Kim, Y. S. Kim, Z. Koutoubi, V. Liakina, Y. S. Lim, A. Löve, M. Maimets, R. Malekzadeh, M. Matičič, M. S. Memon, S. Merat, J. E. Mokhbat, F. H. Mourad, D. H. Muljono, A. Nawaz, N. Nugrahini, S. Olafsson, S. Priohutomo, H. Qureshi, P. Rassam, H. Razavi, D. Razavi‐Shearer, K. Razavi‐Shearer, B. Rozentale, M. Sadik, K. Saeed, A. Salamat, F. M. Sanai, A. Sanityoso Sulaiman, R. A. Sayegh, A. I. Sharara, M. Siddiq, A. M. Siddiqui, G. Sigmundsdottir, B. Sigurdardottir, D. Speiciene, A. Sulaiman, M. A. Sultan, M. Taha, J. Tanaka, H. Tarifi, G. Tayyab, I. Tolmane, M. Ud din, M. Umar, J. Valantinas, J. Videčnik‐Zorman, C. Yaghi, E. Yunihastuti, M. A. Yusuf, B. F. Zuberi & J. D. Schmelzer. (2015) The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3. Journal of Viral Hepatitis 22:S4, pages 21-41.
Crossref
Crossref
A. Hatzakis, V. Chulanov, A. C. Gadano, C. Bergin, Z. Ben‐Ari, J. Mossong, I. Schréter, O. Baatarkhuu, S. Acharya, I. Aho, A. C. Anand, M. I. Andersson, V. Arendt, P. Arkkila, K. Barclay, F. Bessone, S. Blach, N. Blokhina, C. R. Brunton, G. Choudhuri, L. Cisneros, E. A. Croes, Y. A. Dahgwahdorj, O. Dalgard, J. R. Daruich, N. R. Dashdorj, D. Davaadorj, R. J. de Knegt, M. de Vree, C. Estes, R. Flisiak, E. Gane, E. Gower, W. Halota, C. Henderson, P. Hoffmann, J. Hornell, D. Houlihan, S. Hrusovsky, P. Jarčuška, D. Kershenobich, K. Kostrzewska, P. Kristian, M. Leshno, Y. Lurie, A. Mahomed, N. Mamonova, N. Mendez‐Sanchez, S. Norris, E. Nurmukhametova, P. Nymadawa, M. Oltman, J. Oyunbileg, Ts. Oyunsuren, G. Papatheodoridis, N. Pimenov, N. Prabdial‐Sing, M. Prins, S. Radke, A. Rakhmanova, K. Razavi‐Shearer, H. W. Reesink, E. Ridruejo, R. Safadi, O. Sagalova, J. F. Sanchez Avila, R. Sanduijav, V. Saraswat, C. Seguin‐Devaux, S. R. Shah, I. Shestakova, A. Shevaldin, O. Shibolet, M. O. Silva, S. Sokolov, M. Sonderup, K. Souliotis, C. W. Spearman, T. Staub, C. Stedman, E. A. Strebkova, D. Struck, V. Sypsa, K. Tomasiewicz, L. Undram, A. J. van der Meer, D. van Santen, I. Veldhuijzen, F. G. Villamil, S. Willemse, E. Zuckerman, F. R. Zuure, P. Puri & H. Razavi. (2015)
The present and future disease burden of hepatitis
C
virus (
HCV
) infections with today's treatment paradigm – volume 2
. Journal of Viral Hepatitis 22:s1, pages 26-45.
Crossref
Crossref
H. Razavi, P. Bruggmann, H. Wedemeyer & G. Dore. (2014)
Response to letter to the editor: Strategies to reduce
HCV
disease burden and
HCV
transmission need different models, as what works for end‐stage liver disease may not work for
HCV
prevalence: a comment on the results presented in
JVH
Special Issue
. Journal of Viral Hepatitis 21:12.
Crossref
Crossref
H. Razavi, I. Waked, C. Sarrazin, R. P. Myers, R. Idilman, F. Calinas, W. Vogel, M. C. Mendes Correa, C. Hézode, P. Lázaro, U. Akarca, S. Aleman, İ. Balık, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, C. E. Brandão Mello, P. Bruggmann, M. Buti, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. E. Cramp, G. J. Dore, W. Doss, A. S. Duberg, M. H. El‐Sayed, G. Ergör, G. Esmat, K. Falconer, J. Félix, M. L. G. Ferraz, P. R. Ferreira, S. Frankova, J. García‐Samaniego, J. Gerstoft, J. A. Giria, F. L. GonçalesJrJr, E. Gower, M. Gschwantler, M. Guimarães Pessôa, S. J. Hindman, H. Hofer, P. Husa, M. Kåberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, R. T. Marinho, P. Marotta, S. Mauss, C. Moreno, K. Murphy, F. Negro, V. Nemecek, N. Örmeci, A. L. H. Øvrehus, J. Parkes, K. Pasini, K. M. Peltekian, A. Ramji, N. Reis, S. K. Roberts, W. M. Rosenberg, F. Roudot‐Thoraval, S. D. Ryder, R. Sarmento‐Castro, D. Semela, M. Sherman, G. E. Shiha, W. Sievert, J. Sperl, P. Stärkel, R. E. Stauber, A. J. Thompson, P. Urbanek, P. Van Damme, I. van Thiel, H. Van Vlierberghe, D. Vandijck, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, M. Cornberg, B. Müllhaupt & C. Estes. (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis 21:s1, pages 34-59.
Crossref
Crossref
Mehlika Toy. (2013) Cost-effectiveness of viral hepatitis B & C treatment. Best Practice & Research Clinical Gastroenterology 27:6, pages 973-985.
Crossref
Crossref
Homie Razavi, Antoine C. ElKhoury, Elamin Elbasha, Chris Estes, Ken Pasini, Thierry Poynard & Ritesh Kumar. (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57:6, pages 2164-2170.
Crossref
Crossref
A. C. El Khoury, W. K. Klimack, C. Wallace & H. Razavi. (2011) Economic burden of hepatitis C‐associated diseases in the United States. Journal of Viral Hepatitis 19:3, pages 153-160.
Crossref
Crossref
H. Jafferbhoy, M.H. Miller, J.K. Dunbar, J. Tait, S. Mcleod & J.F. Dillon. (2011) Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. Journal of Viral Hepatitis 19:2, pages 112-119.
Crossref
Crossref
Rebecca Townsend, Phil McEwan, Ray Kim & Yong Yuan. (2011) Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. Value in Health 14:8, pages 1068-1077.
Crossref
Crossref
G. Sroczynski, E. Esteban, A. Conrads-Frank, R. Schwarzer, N. Mühlberger, D. Wright, S. Zeuzem & U. Siebert. (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis 17:1, pages 34-50.
Crossref
Crossref
Jennifer A. Tan, Tom A. Joseph & Sammy Saab. (2008) Treating hepatitis C in the prison population is cost-saving. Hepatology 48:5, pages 1387-1395.
Crossref
Crossref
S. James Matthews & Christopher McCoy. 2008. Hepatitis C Virus Disease. Hepatitis C Virus Disease
237
296
.
A. Lonardo, N. Carulli & P. Loria. (2007) HCV and diabetes. Digestive and Liver Disease 39:8, pages 753-761.
Crossref
Crossref